Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:13 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 8,457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism Disorder, Glucose Clear all
Terminated Phase 2 Interventional Results available

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

NCT04964388
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
55 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

NCT03174288
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exercise, Spironolactone
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Nov 3, 2026, 9:13 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

PreventT2 Together: Examining the Efficacy of Couple-based Lifestyle Intervention to Prevent Type 2 Diabetes

NCT06690788
View directory record Official record
Conditions
Prediabetic State, Life Style, Intervention Study, Social Support, Physical Activity, Obesity
Interventions
Individual intervention condition (PreventT2), Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional Results available

Pilot Project of Health Promotion for People With Diabetes

NCT00970294
View directory record Official record
Conditions
Diabetes
Interventions
Health Promotion Program
Behavioral
Lead sponsor
Patricia Kluding, PhD
Other
Eligibility
40 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

NCT00842556
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Glimepiride, Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional Results available

Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes

NCT02409329
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
REACH, Helpline and A1c results, REACH + FAMS
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Nov 3, 2026, 9:13 AM EST
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional

Pilot Stair Climbing Study

NCT02827383
View directory record Official record
Conditions
Prediabetic State
Interventions
Stair Climbing Frequency
Behavioral
Lead sponsor
Jennifer Gay
Other
Eligibility
40 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Nov 3, 2026, 9:13 AM EST
Active, not recruiting Phase 3 Interventional

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

NCT05098470
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Metformin, Insulin Glargine, Dorzagliatin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Nov 3, 2026, 9:13 AM EST
Recruiting Not applicable Interventional

Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART

NCT06405373
View directory record Official record
Conditions
Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions
ReCharge, TakeCharge
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional Results available

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

NCT03091673
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

NCT01042769
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Aleglitazar, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
7,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
221
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 3, 2026, 9:13 AM EST
Terminated Phase 2 Interventional Results available

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

NCT03490942
View directory record Official record
Conditions
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Interventions
Glucagon, Placebo
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 4 Interventional

Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes

NCT02019186
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Vitamin C, Vitamin E
Dietary Supplement
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
8 Years to 15 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

NCT00645827
View directory record Official record
Conditions
Glucose, Blood
Interventions
IICE Dosing, Healthcare Provider dosing
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Nov 3, 2026, 9:13 AM EST
Not yet recruiting Not applicable Interventional

Cardiometabolic & Cognitive Effects of Peanut Butter in Prediabetes

NCT07714096
View directory record Official record
Conditions
Prediabetes
Interventions
Peanut butter, Usual diet
Other
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

NCT02140983
View directory record Official record
Conditions
Insulin Resistance, Dementia
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Nov 3, 2026, 9:13 AM EST
Recruiting No phase listed Observational

Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

NCT06144554
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Omnipod 5
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
2 Years and older
Enrollment
2,200 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Nov 3, 2026, 9:13 AM EST
Completed No phase listed Observational

Sleep Disordered Breathing and Diabetes

NCT00901472
View directory record Official record
Conditions
Type 2 Diabetes, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 3, 2026, 9:13 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
VX-264
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Not listed Phase 1 Interventional Accepts healthy volunteers

The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

NCT02518932
View directory record Official record
Conditions
Insulin Resistance
Interventions
Last 5 amino acids of GLP-1, placebo saline
Drug
Lead sponsor
Elahi, Dariush, PhD
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Nov 3, 2026, 9:13 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Using Signos mHealth Platform in Adults for Weight Management

NCT06214221
View directory record Official record
Conditions
Overweight and Obesity, Metabolic Syndrome, Weight Loss
Interventions
Signos System, Standard Lifestyle Education
Device · Other
Lead sponsor
Signos Inc
Industry
Eligibility
22 Years and older
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Walnut Creek, California • North Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Nov 3, 2026, 9:13 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between Systemic Fatty Acid Availability and Insulin Sensitivity

NCT01452048
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Nov 3, 2026, 9:13 AM EST